Downregulation of ACC expression suppresses cell viability and migration in the malignant progression of breast cancer

Jin,Mei; Yuan,Chunlei; Duan,Sijia; Zeng,Bin; Pan,Lingjuan

doi:10.3892/etm.2023.12144

Downregulation of ACC expression suppresses cell viability and migration in the malignant progression of breast cancer

Authors:
- Mei Jin
- Chunlei Yuan
- Sijia Duan
- Bin Zeng
- Lingjuan Pan
View Affiliations

Affiliations: Department of Galactophore, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Galactophore Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of General Surgery, Nanchang University, Nanchang, Jiangxi, 330031, P.R. China, Department of General Surgery, Fengcheng People's Hospital, Fengcheng, Jiangxi 331100, P.R. China
Published online on: August 2, 2023 https://doi.org/10.3892/etm.2023.12144
Article Number: 445
Copyright: © Jin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Exploring new diagnostic biomarkers and molecular targets is of great importance in breast cancer treatment. The present study investigated the effects of acetyl‑CoA carboxylase (ACC) expression interference on the malignant progression of breast cancer cells. ACC expression was knocked down using a lentiviral vector and this was verified by quantitative polymerase chain reaction and western blotting. MCF‑7 and MDA‑MB‑231 breast cancer cells were randomly allocated into the following groups: Normal breast cancer cells (control), breast cancer cells transduced with a negative control lentiviral vector and breast cancer cells transduced with an ACC knockdown lentiviral vector. Screening for stable transgenic strains was successful. Cell viability, apoptosis and migration were determined using Cell Counting Kit‑8, flow cytometry and scratch test, respectively. The protein expression levels of N‑cadherin, Vimentin and Bax were detected by western blotting. In addition, a nude mouse model of subcutaneous metastatic tumor was established using MCF‑7 breast cancer cells, and tumor volume was assessed. Furthermore, pathological condition and apoptosis were detected using hematoxylin and eosin, and TUNEL staining, respectively. The protein expression levels of N‑cadherin, Vimentin and Bax were detected by western blotting. The in vitro experiments showed that knockdown of ACC expression significantly decreased the viability and migration, and increased the apoptosis of MCF‑7 and MDA‑MB‑231 breast cancer cells. In vivo experiments revealed that ACC knockdown effectively reduced the tumor volume in nude mice, and promoted tumor cell apoptosis. Both in vitro and in vivo experiments showed that ACC knockdown can reduce the protein expression levels of N‑cadherin and Vimentin, and increase Bax expression. These findings suggested that downregulation of ACC expression may significantly reduce the malignant progression of breast cancer, and could be considered a potential therapeutic target.

View Figures

View References

1	Dowsett M: Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res. 9:502S–510S. 2003.PubMed/NCBI
2	Youness RA, Gad AZ, Sanber K, Ahn YJ, Lee GJ, Khallaf E, Hafez HM, Motaal AA, Ahmed N and Gad MZ: Targeting hydrogen sulphide signaling in breast cancer. J Adv Res. 27:177–190. 2020.PubMed/NCBI View Article : Google Scholar
3	Viedma-Rodríguez R, Baiza-Gutman L, Salamanca-Gómez F, Diaz-Zaragoza M, Martínez-Hernández G, Ruiz Esparza-Garrido R, Velázquez-Flores MA and Arenas-Aranda D: Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review). Oncol Rep. 32:3–15. 2014.PubMed/NCBI View Article : Google Scholar
4	Chen L, Duan Y, Wei H, Ning H, Bi C, Zhao Y, Qin Y and Li Y: Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors. Expert Opin Investig Drugs. 28:917–930. 2019.PubMed/NCBI View Article : Google Scholar
5	Corbett JW: Review of recent acetyl-CoA carboxylase inhibitor patents: Mid-2007-2008. Expert Opin Ther Pat. 19:943–956. 2009.PubMed/NCBI View Article : Google Scholar
6	Zhan Y, Ginanni N, Tota MR, Wu M, Bays NW, Richon VM, Kohl NE, Bachman ES, Strack PR and Krauss S: Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells. Clin Cancer Res. 14:5735–5742. 2008.PubMed/NCBI View Article : Google Scholar
7	Zhao S, Cheng L, Shi Y, Li J, Yun Q and Yang H: MIEF2 reprograms lipid metabolism to drive progression of ovarian cancer through ROS/AKT/mTOR signaling pathway. Cell Death Dis. 12(18)2021.PubMed/NCBI View Article : Google Scholar
8	Ye B, Yin L, Wang Q and Xu C: ACC1 is overexpressed in liver cancers and contributes to the proliferation of human hepatoma Hep G2 cells and the rat liver cell line BRL 3A. Mol Med Rep. 19:3431–3440. 2019.PubMed/NCBI View Article : Google Scholar
9	Fang W, Cui H, Yu D, Chen Y, Wang J and Yu G: Increased expression of phospho-acetyl-CoA carboxylase protein is an independent prognostic factor for human gastric cancer without lymph node metastasis. Med Oncol. 31(15)2014.PubMed/NCBI View Article : Google Scholar
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
11	Zhou J, Chen C, Zhao X, Jiang T, Jiang Y, Dai J and Chen J: Coding variants in the PCNT and CEP295 genes contribute to breast cancer risk in Chinese women. Pathol Res Pract. 225(153581)2021.PubMed/NCBI View Article : Google Scholar
12	Miller EA, Pinsky PF, Heckman-Stoddard BM and Minasian LM: Breast cancer risk prediction models and subsequent tumor characteristics. Breast Cancer. 27:662–669. 2020.PubMed/NCBI View Article : Google Scholar
13	Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, Van Veldhoven PP, Waltregny D, Daniëls VW, Machiels J, et al: De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 70:8117–8126. 2010.PubMed/NCBI View Article : Google Scholar
14	Schreurs M, Kuipers F and van der Leij FR: Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome. Obes Rev. 11:380–388. 2010.PubMed/NCBI View Article : Google Scholar
15	Harwood HJ Jr: Treating the metabolic syndrome: Acetyl-CoA carboxylase inhibition. Expert Opin Ther Targets. 9:267–281. 2005.PubMed/NCBI View Article : Google Scholar
16	Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, Wang A, Zhang XM, Cline GW, Yu XX, Geisler JG, et al: Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest. 116:817–824. 2006.PubMed/NCBI View Article : Google Scholar
17	Kusunoki J, Kanatani A and Moller DE: Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome. Endocrine. 29:91–100. 2006.PubMed/NCBI View Article : Google Scholar
18	Srivastava RA, Jahagirdar R, Azhar S, Sharma S and Bisgaier CL: Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol Cell Biochem. 285:35–50. 2006.PubMed/NCBI View Article : Google Scholar
19	Pang B, Zhang J, Zhang X, Yuan J, Shi Y and Qiao L: Inhibition of lipogenesis and induction of apoptosis by valproic acid in prostate cancer cells via the C/EBPα/SREBP-1 pathway. Acta Biochim Biophys Sin (Shanghai). 53:354–364. 2021.PubMed/NCBI View Article : Google Scholar
20	Göbel A, Dell'Endice S, Jaschke N, Pählig S, Shahid A, Hofbauer LC and Rachner TD: The role of inflammation in breast and prostate cancer metastasis to bone. Int J Mol Sci. 22(5078)2021.PubMed/NCBI View Article : Google Scholar
21	Tong D: Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype. Crit Rev Oncol Hematol. 163(103370)2021.PubMed/NCBI View Article : Google Scholar
22	Barik GK, Sahay O, Behera A, Naik D and Kalita B: Keep your eyes peeled for long noncoding RNAs: Explaining their boundless role in cancer metastasis, drug resistance, and clinical application. Biochim Biophys Acta Rev Cancer. 1876(188612)2021.PubMed/NCBI View Article : Google Scholar
23	González-Martínez S, Pérez-Mies B, Pizarro D, Caniego-Casas T, Cortés J and Palacios J: Epithelial mesenchymal transition and immune response in metaplastic breast carcinoma. Int J Mol Sci. 22(7398)2021.PubMed/NCBI View Article : Google Scholar
24	Lu Y, Ding Y, Wei J, He S, Liu X, Pan H, Yuan B, Liu Q and Zhang J: Anticancer effects of traditional chinese medicine on epithelial-mesenchymal transition (EMT) in breast cancer: Cellular and molecular targets. Eur J Pharmacol. 907(174275)2021.PubMed/NCBI View Article : Google Scholar